Never Miss Important Company Updates Again
Get AI-powered summaries of SEC filings delivered to your inbox
Follow your favorite stocks and get email alerts when they release important updates. Completely free.
Iovance Biotherapeutics develops personalized TIL (tumor infiltrating lymphocyte) cell therapies for solid tumor cancers, including melanoma and lung cancer. Its core products include Amtagvi, the first FDA-approved TIL therapy for melanoma, and Proleukin, an IL-2 product. The company focuses on manufacturing scalable, proprietary processes and advancing innovative, genetically modified TIL treatments to target diverse, patient-specific neoantigens in global oncology markets.
This description was generated via AI from an annual report. Updated about 1 year ago.